Analysts Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Target Price at $9.50

Quince Therapeutics, Inc. (NASDAQ:QNCX) has received a consensus rating of “Buy” from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $9.50.

A number of research firms have weighed in on QNCX. Brookline Capital Management began coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They set a “buy” rating and a $9.00 price target on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Quince Therapeutics in a research note on Wednesday, February 5th.

Hedge Funds Weigh In On Quince Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Northern Trust Corp raised its stake in shares of Quince Therapeutics by 48.5% in the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after acquiring an additional 16,501 shares during the period. Anfield Capital Management LLC purchased a new position in shares of Quince Therapeutics in the 4th quarter valued at $50,000. Virtu Financial LLC purchased a new position in shares of Quince Therapeutics in the 4th quarter valued at $55,000. Two Sigma Investments LP purchased a new position in shares of Quince Therapeutics in the 4th quarter valued at $57,000. Finally, Geode Capital Management LLC raised its stake in shares of Quince Therapeutics by 10.9% in the 4th quarter. Geode Capital Management LLC now owns 375,932 shares of the company’s stock valued at $703,000 after acquiring an additional 36,807 shares during the period. Hedge funds and other institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Stock Performance

Shares of QNCX opened at $1.37 on Tuesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. The company has a market capitalization of $60.28 million, a price-to-earnings ratio of -1.10 and a beta of 0.71. The company’s 50 day simple moving average is $1.51 and its 200 day simple moving average is $1.42. Quince Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.45.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.